Andrew Cheng - 07 Dec 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President and CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 07 Dec 2023
Net transactions value: -$368,388
Form type: 4
Filing time: 11 Dec 2023, 20:59:21 UTC
Previous filing: 04 Oct 2023
Next filing: 18 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$42,612	+6,700	+1.5%	$6.36	467,698	07 Dec 2023	Direct	F1
transaction	AKRO	Common Stock	Sale	$134,125	-6,700	-1.4%	$20.02	460,998	07 Dec 2023	Direct	F1, F2
transaction	AKRO	Common Stock	Options Exercise	$81,872	+12,873	+2.8%	$6.36	473,871	08 Dec 2023	Direct	F1
transaction	AKRO	Common Stock	Sale	$257,571	-12,873	-2.7%	$20.01	460,998	08 Dec 2023	Direct	F1, F3
transaction	AKRO	Common Stock	Award	$0	+91,541	+20%	$0.000000	552,539	08 Dec 2023	Direct	F4
transaction	AKRO	Common Stock	Options Exercise	$47,096	+7,405	+1.3%	$6.36	559,944	11 Dec 2023	Direct	F1
transaction	AKRO	Common Stock	Sale	$148,273	-7,405	-1.3%	$20.02	552,539	11 Dec 2023	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-6,700	-17%	$0.000000	33,300	07 Dec 2023	Common Stock	6,700	$6.36	Direct	F1, F6
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-12,873	-39%	$0.000000	20,427	08 Dec 2023	Common Stock	12,873	$6.36	Direct	F1, F6
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+411,936		$0.000000	411,936	08 Dec 2023	Common Stock	411,936	$19.87	Direct	F7
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-7,405	-36%	$0.000000	13,022	11 Dec 2023	Common Stock	7,405	$6.36	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5) to this Form 4.
F3	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.03, inclusive.
F4	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F5	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.13, inclusive.
F6	The options are vested and currently exercisable.
F7	This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.